SB
CTNM

Samsara BioCapital’s Contineum Therapeutics CTNM Stock Holding History

Samsara BioCapital’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-72,245
Closed -$826K – 24
2025
Q4 		$826K Sell
72,245
-498,897
-87% -$5.69M 0.09% 20
2025
Q3 		$6.71M Sell
571,142
-17,674
-3% -$142K 0.88% 15
2025
Q2 		$2.34M Hold
588,816
– – 0.48% 20
2025
Q1 		$4.11M Hold
588,816
– – 0.73% 18
2024
Q4 		$8.63M Hold
588,816
– – 1.18% 15
2024
Q3 		$11.3M Sell
588,816
-1
-0% -$19 2.17% 13
2024
Q2 		$10.4M Buy
+588,817
New +$9.48M 2.17% 14

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Samsara BioCapital's CTNM Position: Q1 2026 in Review

Samsara BioCapital sold out of Contineum Therapeutics (CTNM) in Q1 2026, closing a stake of 72,245 shares — an estimated $826K sold.

Samsara BioCapital first reported a position in CTNM in Q2 2024 and held it in 7 quarters. The position peaked at $11.3M in Q3 2024. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Samsara BioCapital reported no remaining Contineum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Samsara BioCapital sold 72,245 Contineum Therapeutics shares in Q1 2026, an estimated $826K.
  • Samsara BioCapital first reported a position in Contineum Therapeutics in Q2 2024 and held it in 7 quarters.
  • Samsara BioCapital's Contineum Therapeutics position peaked at $11.3M in Q3 2024.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Samsara BioCapital's 13F filing for Q1 2026, filed 15 May 2026.